Literature DB >> 20107195

Dietary, lifestyle, and clinical predictors of lipoprotein-associated phospholipase A2 activity in individuals without coronary artery disease.

Ida J Hatoum1, Jeanenne J Nelson, Nancy R Cook, Frank B Hu, Eric B Rimm.   

Abstract

BACKGROUND: Elevated lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) may be positively associated with risk of coronary artery disease, yet little is known about potentially modifiable factors related to Lp-PLA(2).
OBJECTIVE: The aim of this study was to determine dietary, lifestyle, and clinical measures associated with Lp-PLA(2) activity.
DESIGN: We measured Lp-PLA(2) activity in 853 female participants of the Nurses' Health Study and 878 male participants of the Health Professionals Follow-Up Study who were free of cancer and cardiovascular disease. Multivariable linear regression models were used to assess the relation between potentially modifiable factors and Lp-PLA(2).
RESULTS: The replacement of 5% of energy from carbohydrates with energy from protein was associated with 2.2 nmol . min(-1) . mL(-1) lower levels of Lp-PLA(2) (95% CI: -3.1, -0.4) activity, and every 15-g/d increase in alcohol consumption was associated with 4.4 nmol . min(-1) . mL(-1) lower levels of Lp-PLA(2) activity (95% CI: -6.4, -2.4). Smoking (beta = 10.2; 95% CI: 4.8, 15.5), being overweight (beta = 7.5; 95% CI: 3.6, 11.3), aspirin use (beta = 6.0; 95% CI: 2.1, 10.0), hypercholesterolemia (beta = 15.0; 95% CI: 11.3, 18.8), and age (beta = 2.5; 95% CI: 1.34, 3.74) were associated with elevated Lp-PLA(2) activity, whereas postmenopausal hormone use (beta = -15.8; 95% CI: -19.4, -12.1) and cholesterol medication use (beta = -9.6; 95% CI: -18.2, -1.1) were inversely associated.
CONCLUSION: We found that not smoking, use of postmenopausal hormones, having a body mass index (in kg/m(2)) < or =25, increased alcohol consumption, and increased protein consumption all represent potential modifiable factors that may favorably influence Lp-PLA(2) activity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20107195      PMCID: PMC2824159          DOI: 10.3945/ajcn.2009.28870

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  53 in total

1.  Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors.

Authors:  E B Rimm; P Williams; K Fosher; M Criqui; M J Stampfer
Journal:  BMJ       Date:  1999-12-11

2.  Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data.

Authors:  W Y Craig; G E Palomaki; J E Haddow
Journal:  BMJ       Date:  1989-03-25

3.  Cholesteryl ester accumulation in macrophages incubated with low density lipoprotein pretreated with cigarette smoke extract.

Authors:  M Yokode; T Kita; H Arai; C Kawai; S Narumiya; M Fujiwara
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

4.  Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death.

Authors:  Heidi T May; Benjamin D Horne; Jeffrey L Anderson; Robert L Wolfert; Joseph B Muhlestein; Dale G Renlund; Jessica L Clarke; Matthew J Kolek; Tami L Bair; Robert R Pearson; Krishnankutty Sudhir; John F Carlquist
Journal:  Am Heart J       Date:  2006-11       Impact factor: 4.749

5.  Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis.

Authors:  Stefan Blankenberg; Dominique Stengel; Hans J Rupprecht; Christoph Bickel; Jürgen Meyer; François Cambien; Laurence Tiret; Ewa Ninio
Journal:  J Lipid Res       Date:  2003-05-01       Impact factor: 5.922

6.  Reproducibility and validity of a semiquantitative food frequency questionnaire.

Authors:  W C Willett; L Sampson; M J Stampfer; B Rosner; C Bain; J Witschi; C H Hennekens; F E Speizer
Journal:  Am J Epidemiol       Date:  1985-07       Impact factor: 4.897

Review 7.  Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease.

Authors:  Muriel J Caslake; Chris J Packard
Journal:  Curr Opin Lipidol       Date:  2003-08       Impact factor: 4.776

8.  Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany.

Authors:  Wolfgang Koenig; Natalie Khuseyinova; Hannelore Löwel; Gerlinde Trischler; Christa Meisinger
Journal:  Circulation       Date:  2004-09-27       Impact factor: 29.690

9.  Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor.

Authors:  D M Stafforini; T M McIntyre; M E Carter; S M Prescott
Journal:  J Biol Chem       Date:  1987-03-25       Impact factor: 5.157

10.  Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Christie M Ballantyne; Ron C Hoogeveen; Heejung Bang; Josef Coresh; Aaron R Folsom; Gerardo Heiss; A Richey Sharrett
Journal:  Circulation       Date:  2004-02-02       Impact factor: 29.690

View more
  16 in total

1.  Circulating Lp-PLA₂ activity correlates with oxidative stress and cytokines in overweight/obese postmenopausal women not using hormone replacement therapy.

Authors:  Jean Kyung Paik; Minkyung Kim; Minjoo Kim; Yuna Yen; Hyeon Yeong Ahn; Sang-Hyun Lee; Jong Ho Lee
Journal:  Age (Dordr)       Date:  2015

2.  The relation of diet with PAF and its metabolic enzymes in healthy volunteers.

Authors:  P Detopoulou; E Fragopoulou; T Nomikos; M Yannakoulia; G Stamatakis; D B Panagiotakos; S Antonopoulou
Journal:  Eur J Nutr       Date:  2014-03-18       Impact factor: 5.614

3.  Replacing with whole grains and legumes reduces Lp-PLA2 activities in plasma and PBMCs in patients with prediabetes or T2D.

Authors:  Minjoo Kim; Se Ri Jeung; Tae-Sook Jeong; Sang-Hyun Lee; Jong Ho Lee
Journal:  J Lipid Res       Date:  2014-06-05       Impact factor: 5.922

Review 4.  Effects of dietary factors on lipoprotein-associated phospholipase A(2) (Lp-PLA (2)).

Authors:  Cheuk-Kit Wong; Harvey D White
Journal:  Curr Atheroscler Rep       Date:  2011-12       Impact factor: 5.113

Review 5.  Effects of ethanol intake on lipoproteins.

Authors:  Eliot A Brinton
Journal:  Curr Atheroscler Rep       Date:  2012-04       Impact factor: 5.113

6.  Lipoprotein associated phospholipase A(2): role in atherosclerosis and utility as a biomarker for cardiovascular risk.

Authors:  Kenneth J Colley; Robert L Wolfert; Michael E Cobble
Journal:  EPMA J       Date:  2011-03-10       Impact factor: 6.543

7.  Therapeutic Options to Reduce Lp-PLA2 Levels and the Potential Impact on Vascular Risk Reduction.

Authors:  Koto Ishida; Brett Cucchiara
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-06

8.  n-3 and n-6 Fatty acids are independently associated with lipoprotein-associated phospholipase A2 in the Multi-Ethnic Study of Atherosclerosis.

Authors:  Brian T Steffen; Lyn M Steffen; Shuang Liang; Russell Tracy; Nancy Swords Jenny; Michael Y Tsai
Journal:  Br J Nutr       Date:  2013-04-03       Impact factor: 3.718

9.  Influence of obesity and cardiometabolic makers on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in adolescents: the healthy young cross-sectional study.

Authors:  Isis T da Silva; Anelise de Souza Timm; Nágila R T Damasceno
Journal:  Lipids Health Dis       Date:  2013-02-15       Impact factor: 3.876

Review 10.  Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A₂ (Lp-PLA₂): a review.

Authors:  Isis T Silva; Ana P Q Mello; Nágila R T Damasceno
Journal:  Lipids Health Dis       Date:  2011-09-28       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.